In December 2019, the Food and Drug Administration (FDA) approved olaparib (Lynparza) for the frontline maintenance treatment of patients with BRCA-positive pancreatic cancer.
This was a major advancement for this patient subset, explained Teresa Marcarulla, MD, a gastrointestinal medical oncologist at the Vall d’Hebron Institute of Oncology. Watch here. . .